Incyte (INCY) Misses Q3 EPS by 14c; Boosts FY15 Jakafi Net Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Incyte Reports 2015 Third-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
November 3, 2015 7:00 AM EST- $161 million of 2015 third-quarter net product revenues from Jakafi® (ruxolitinib), representing 65 percent growth over the same period last year
- Positive results from two pivotal trials of baricitinib to be highlighted at ACR; baricitinib superior to both methotrexate (RA-BEGIN) and to Humira® (adalimumab) (RA-BEAM) in reducing the signs and symptoms of rheumatoid arthritis
- Agreement announced with Merck to expand clinical collaboration to include a pivotal trial of epacadostat plus pembrolizumab in first-line advanced or metastatic melanoma; proof-of-concept data from the ongoing Phase I/II trial to be presented at SITC
... More